Researchers led by metabolism expert Prof Timo D. Müller at Helmholtz Munich have developed a new strategy to treat obesity and type 2 diabetes. Their approach uses a specially designed hybrid molecule that takes advantage of the well-known GLP-1/GIP signalling pathway as a kind of entry point into cells. Once inside, it delivers an additional metabolic compound directly where it is needed. In laboratory tests, mice treated with this compound ate less food, lost more weight, and showed better blood-glucose control than those given standard comparison treatments. The findings were published as a preclinical study in the journal Nature . Limits of Current GLP-1-Based Therapies Modern incretin therapies, which mimic natural satiety and blood sugar signals (GLP-1/GIP), have significantly improved treatment options for obesity and type 2 diabetes. Still, researchers are looking for ways to enhance these therapies further.…